Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00620243 · ClinicalTrials.gov registry record · Early Phase 1

Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.

A Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
9
Enrollment target

NCT00620243: Completed Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00620243 is a Early Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00620243, a Early Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
9 participants
Enrollment target

Study Summary

We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential toxic therapy in non- responders leading to a significant decrease in morbidity and cost. The value of PET imaging as an early predictor of response to chemotherapy has been shown in other cancers.

Interventions

  • PROCEDURE 1: FDG PET

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2004-06
Est. Completion 2008-11
Phase Early Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00620243 record still lists

NCT00620243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which 1: FDG PET is the first listed.

NCT00620243 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00620243 about?

NCT00620243 is a clinical study titled "Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.". We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential toxic therapy in non- responders leading to a significant decrease in morbidity and cost. The value of...

What is the current status of trial NCT00620243?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2004-06. Estimated completion is 2008-11.

What interventions are being tested in trial NCT00620243?

The interventions under investigation include: 1: FDG PET (PROCEDURE).

Who is sponsoring clinical trial NCT00620243?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00620243's enrollment target sits among peer trials

9 1746th of 2000 higher than 219 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00620243, the US trial registry maintained by the National Library of Medicine. NCT00620243 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.